Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of Avelumab in Solid Tumors
NCT03815643Phase 3Active, not recruiting
- Sponsor
- EMD Serono
- Start
- Mar 2019
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
A Phase 3 trial of avelumab in solid tumor, sponsored by EMD Serono. Started Mar 2019; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03815643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815643.